The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators
Learn how PBPK and QSP modeling support regulatory confidence, accelerate drug development, and align with…
Certara2026 年 5 月 26 日
FDA Rebuilding After DOGE Cuts: Former Regulators Speak Out
Former FDA officials describe the impact of DOGE-era staffing cuts, lost expertise, and the challenges…
Certara2026 年 5 月 15 日
How to Leverage PBPK Modeling and Simulation in Drug Research and Development
Learn how PBPK modeling and simulation in drug research and development reduces clinical burden, supports…
Certara2026 年 5 月 12 日
How Pharma Can Transition to Non-animal Studies for Investigational Drugs
Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…
Certara2026 年 5 月 5 日
From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development
Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…
Certara2026 年 4 月 28 日
ToxStudio® Predictive Toxicology Software
Learn about ToxStudio: Predictive toxicology software to support prediction of drug-induced liver injury (DILI), QT…
Certara2026 年 4 月 16 日
FDA Blueprint Aims To Cut Regulatory Risk for Alternatives to Animal Testing
The FDA’s new draft guidance clarifies how drug developers can validate and use non-animal testing…
Certara2026 年 4 月 1 日
Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations
Learn how regulatory expectations in clinical pharmacology are evolving and how to build a strategy…
Certara2026 年 3 月 24 日
